Medivation Inc (MDVN), Amarin Corporation plc (ADR) (AMRN), Abbott Laboratories (ABT): Adage Capital Management Owns 5.4% of This Company

According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation Inc (NASDAQ:MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has roughly doubled the size of its position. Find more of Adage’s stock picks. Biotechnology stocks have generally been strong this year, though Medivation Inc (NASDAQ:MDVN) is actually an exception having fallen year to date. Currently, Medivation Inc (NASDAQ:MDVN) primarily markets Xtandi, a cancer drug, to post-chemotherapy prostate cancer patients; the company is also studying the use of the drug in other contexts.

Xtandi launched last year and as a general rule the drug has been found to be more effective than competing drugs with some question as to the prevalence of side effects in some groups of patients (which may lead to it being a second-choice drug). Still, revenue numbers have been good and there is at least a prospect of the drug finding wider use if it is approved in other markets (including pre-chemotherapy prostate cancer). As a development stage company Medivation is unprofitable, and cash flow from operations was negative in 2012 as well at a net of about $100 million in cash used. At the end of the year there was about $300 million in cash, cash equivalents, and short term investments on the balance sheet so at least in the short term there should be few cash concerns.

Andreas Halvorsen

Analyst consensus is for earnings per share of 41 cents in 2014, with a wide range of estimates (from $1.93 per share to a loss of 50 cents per share). Billionaire and Tiger Cub Andreas Halvorsen’s Viking Global had been selling shares of Medivation Inc (NASDAQ:MDVN) between October and December of last year, but still closed 2012 with 3.4 million shares in its portfolio (see Halvorsen’s favorite stocks). Orbimed Advisors, a healthcare-focused fund managed by Sam Isaly, reported owning 1.4 million shares at the end of the fourth quarter (check out more stocks Isaly likes).

Other development stage biotechnology companies include Dendreon (NASDAQ:DNDN) and Amarin Corporation plc (ADR) (NASDAQ:AMRN). Consensus is that both of these companies will be unprofitable this year as well as in 2014, so any investment in them is at least as speculative as buying Medivation Inc (NASDAQ:MDVN). Dendreon’s lead product Provenge is also a prostate cancer drug, with the company working on other cancer treatments as well. The stock price has fallen 55% in the last year, and the most recent data shows that 34% of the float is held short so there continues to be a sizable bearish community. Amarin Corporation plc (ADR) (NASDAQ:AMRN) is also down considerably from its levels a year ago, and is also a popular short target; Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s lead product is designed to reduce triglyceride levels.

We can also compare Medivation Inc (NASDAQ:MDVN) to larger biotech companies including Abbott Laboratories (NYSE:ABT) and Biogen (NASDAQ:BIIB). These companies both generated positive earnings in 2012, though in Biogen’s case the trailing P/E is quite high at 34. While its recent financial performance has not been particularly encouraging- in the fourth quarter of 2012, revenue increased only 7% versus a year earlier and earnings were actually down slightly- the sell-side is expecting improvements in net income over the next couple years and so the forward P/E is only 20. We still think that we would avoid the stock for now. Abbott Laboratories (NYSE:ABT), meanwhile, carries a forward P/E of 16. It’s also not been in a particularly good situation, with earnings falling 35% in its most recent quarterly report compared to the fourth quarter of 2011.

We do expect earnings of these biotech companies to be a bit noisy but at this point it looks to us that Abbott Laboratories (NYSE:ABT) is too speculative to treat as a value stock as well as Biogen. The other three companies we’ve covered here, including Medivation, are yet to be profitable as well and so we’d advise against buying them as well. We do think that Medivation looks to be an unwise short given the emerging success of its drug and the sizable cash on the company’s balance sheet as it attempts to bring Xtandi into additional markets.

Disclosure: I own no shares of any stocks mentioned in this article.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!